Guardant Health vs Veracyte
GH and VCYT side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GH and VCYT compare
Guardant Health is the larger company, worth 6.0 times as much as Veracyte ($24.0B against $4.0B).
Guardant Health grew revenue faster over the last twelve months (42.7% versus 17.3% for Veracyte).
Veracyte keeps more of each dollar of sales as profit, with a net margin of 20.4% compared with −38.3% at Guardant Health.
Veracyte scores higher on the StockData Score (13 against 9 for Guardant Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GH | VCYT |
|---|---|---|
| Size and price | ||
| Market cap | $24.0B | $4.0B |
| Share price | $178.80 | $50.01 |
| Change, 1 year | 147% | 41.2% |
| Change, 5 years | 62.3% | 0.10% |
| Beta (5Y) | 1.61 | 1.69 |
| Employees | 2,506 | 755 |
| StockData Score | ||
| Total score | 9 | 13 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 3 | 3 |
| Performance score | 1 | 3 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 35.7× |
| P/S | 20.3× | 7.2× (better) |
| P/B | – | 2.9× |
| EV/EBITDA | – | 29.4× |
| P/FCF | – | 24.2× |
| FCF yield | −1.0% | 4.1% (better) |
| Fair value | – | $41.65 |
| Margin of safety | – | −20.1% |
| Growth | ||
| Revenue growth (TTM) | 42.7% (better) | 17.3% |
| Revenue growth, 5Y average | 27.9% | 34.5% (better) |
| Net income growth (TTM) | – | 335% |
| EPS growth (TTM) | – | 324% |
| Profitability | ||
| Gross margin | 65.0% | 71.7% (better) |
| Operating margin | −39.7% | 18.8% (better) |
| Net margin | −38.3% | 20.4% (better) |
| FCF margin | −20.3% | 29.5% (better) |
| Return on equity | – | 8.8% |
| Return on invested capital | – | 10.0% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −97.6× | – |
| Current ratio | 4.03 | 9.16 (better) |
| Altman Z-score | 4.83 | 25.35 (better) |
| Piotroski F-score | 6 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 99.8% | 111% |
| Held by insiders | 1.9% | 1.7% |
| Insider net buying, 12 months | −$174M | −$21.0M (better) |
| Short interest, % of float | 9.1% | 12.9% |
Go deeper
- GH stock overview
- GH income statement
- GH valuation and score
- VCYT stock overview
- VCYT income statement
- VCYT valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.